Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Bandelow

Showing results (31-40 of 80) with videos related to

Pageof 8
Sort By:
International Clinical Psychopharmacology|June 1, 1995
Assessing the efficacy of treatments for panic disorder and agoraphobia. I. Methodological problemsB Bandelow, G Hajak, S Holzrichter, et al.
International Journal of Sports Medicine|December 5, 1998
Endurance training in panic patients: spiroergometric and clinical effectsT Meyer, A Broocks, B Bandelow, et al.
Fortschritte Der Neurologie-Psychiatrie|March 8, 2000
[New antidepressive drugs in comparison with classical tricyclics. Mechanism of action and clinical evaluation]A Broocks, K Junghanns, A Thiel, et al.
Journal of Pineal Research|October 1, 1995
Nocturnal plasma melatonin levels in patients suffering from chronic primary insomniaG Hajak, A Rodenbeck, J Staedt, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 1, 1996
Nocturnal plasma melatonin levels after flunitrazepam administration in healthy subjectsG Hajak, A Rodenbeck, B Bandelow, et al.
The American Journal of Psychiatry|March 4, 2000
Salivary cortisol in panic attacksB Bandelow, D Wedekind, J Pauls, et al.
Zeitschrift Fur Psychosomatische Medizin Und Psychotherapie|October 11, 2001
[Cortisol in night-urine: Introduction of a research method in psychoneuroendocrinology]S Doering, D Wedekind, J Pilz, et al.
Fortschritte Der Neurologie-Psychiatrie|November 1, 1995
[Panic disorder and agoraphobia: what is effective?]B Bandelow, K Sievert, M Röthemeyer, et al.
Pharmacopsychiatry|February 12, 2005
Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challengesG Kronenberg, P Berger, R F Tauber, et al.
Neuroreport|September 8, 2000
Plasma homocysteine is a predictor of alcohol withdrawal seizuresS Bleich, D Degner, B Bandelow, et al.
Pageof 8

Showing results (31-40 of 80) with videos related to

Sort By:
Pageof 8
International Clinical Psychopharmacology|June 1, 1995
Assessing the efficacy of treatments for panic disorder and agoraphobia. I. Methodological problemsB Bandelow, G Hajak, S Holzrichter, et al.
International Journal of Sports Medicine|December 5, 1998
Endurance training in panic patients: spiroergometric and clinical effectsT Meyer, A Broocks, B Bandelow, et al.
Fortschritte Der Neurologie-Psychiatrie|March 8, 2000
[New antidepressive drugs in comparison with classical tricyclics. Mechanism of action and clinical evaluation]A Broocks, K Junghanns, A Thiel, et al.
Journal of Pineal Research|October 1, 1995
Nocturnal plasma melatonin levels in patients suffering from chronic primary insomniaG Hajak, A Rodenbeck, J Staedt, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|May 1, 1996
Nocturnal plasma melatonin levels after flunitrazepam administration in healthy subjectsG Hajak, A Rodenbeck, B Bandelow, et al.
The American Journal of Psychiatry|March 4, 2000
Salivary cortisol in panic attacksB Bandelow, D Wedekind, J Pauls, et al.
Zeitschrift Fur Psychosomatische Medizin Und Psychotherapie|October 11, 2001
[Cortisol in night-urine: Introduction of a research method in psychoneuroendocrinology]S Doering, D Wedekind, J Pilz, et al.
Fortschritte Der Neurologie-Psychiatrie|November 1, 1995
[Panic disorder and agoraphobia: what is effective?]B Bandelow, K Sievert, M Röthemeyer, et al.
Pharmacopsychiatry|February 12, 2005
Randomized, double-blind study of SR142801 (Osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challengesG Kronenberg, P Berger, R F Tauber, et al.
Neuroreport|September 8, 2000
Plasma homocysteine is a predictor of alcohol withdrawal seizuresS Bleich, D Degner, B Bandelow, et al.
Pageof 8